The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Lung Cancer Clinical Trial

Official title:

A Preliminary Study on the Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05735028
• Other study ID #: 2022-0826
• Status: Recruiting
• Phase: Phase 1
• Start date: February 7, 2024
• Est. completion date: December 7, 2025

Study information

• Verified date: March 2024
• Source: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Contact: Ying Dong, Doctorate
• Phone: 13666669105
• Email: dongying74[@]zju.edu.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Lung cancer has a high global cancer morbidity and mortality. At present, PD-1/PD-L1 inhibitors have been approved by FDA to treat different types of lung cancer, but the efficacy is not good. There is an urgent need to develop drugs that can significantly enhance the efficacy of PD-1/PD-L1 inhibitors to enable tumor patients to obtain lasting anti-tumor response. Centipeda minima (CM), as a commonly used traditional Chinese medicine, is relatively safe. Previous studies found that it can inhibit the growth of lung cancer cells. At the level of animal research, the combined use of CM and PD-1/PD-L1 inhibitors produced a stronger anti-lung cancer effect, and did not produce obvious side effects on mice. Based on previous studies, the main purpose of this study was to evaluate the efficacy and safety of PD-1/PD-L inhibitors combined with herbivorous herbivores (CM) in the treatment of lung cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 8
• Est. completion date: December 7, 2025
• Est. primary completion date: August 7, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

Patients with non-small cell lung cancer diagnosed by histopathology and intended to be treated with PD-1/PD-L1 inhibitors alone meet the following conditions:

1. Patients fully understand this study and voluntarily participate in and sign informed consent.

2. Patients with non-small cell lung cancer (NSCLC) confirmed by histopathology will be treated with PD-1/PD-L1 alone.

3. 18-70 years old, and the expected survival time is more than 6 months.

4. The indexes of stool routine are normal.

Exclusion Criteria:

1. Patients who plan to receive other traditional Chinese medicine treatment at the same time during the study period.

2. Those who are hypersensitive to any research drugs or ingredients

3. Those who have severe acute infection and are not controlled; or those who have suppurative and chronic infection and whose wounds are not healed.

4. Obvious gastrointestinal diseases during screening, such as inability to swallow, chronic diarrhea, intestinal obstruction, gastric ulcer and so on.

5. Those who have participated in clinical trials of other drugs within 5 or 4 weeks.

6. Patients with severe heart disease, including congestive heart failure, uncontrollable high-risk arrhythmias, unstable angina pectoris, myocardial infarction, severe valvular heart disease and intractable hypertension.

7. Suffering from uncontrollable neurological, mental illness or mental disorders, poor compliance, unable to cooperate and describe the treatment response. Primary brain tumor or central nervous system metastasis is not controlled, with obvious intracranial hypertension or neuropsychiatric symptoms.

8. Those with bleeding tendency; evidence of hereditary hemorrhagic physique or blood coagulation disorder

9. Severe allergic / allergic reaction to humanized antibody.

10. Diagnosed with immunodeficiency or receiving systemic glucocorticoid therapy or any other form of immunosuppressive therapy within 14 days prior to the first administration of the study, allowing the use of physiological doses of glucocorticoids (prednisone or equivalent for = 10mg/ days).

11. Exclude subjects with active, known or suspected autoimmune diseases (such as interstitial pneumonia, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hypothyroidism, including but not limited to these diseases or syndromes).

12. Vulnerable groups: such as patients with serious diseases, incapacitated, illiterate, mentally retarded / related mental disorders, children.

-

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• Centipeda minima+PD-1/PD-L1 inhibitor
Before routine anti-PD-1/PD-L1 treatment, patients were treated with Centipeda minima, and15g Centipeda minima decoction was taken twice a day for 5 consecutive days.
• PD-1/PD-L1 inhibitor
PD-1/PD-L1 inhibitor

Locations

Country	Name	City	State
China	The Second Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou

Sponsors (1)

Lead Sponsor	Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival (PFS)	Progression-free survival	through study completion, an average of 2 year.
Primary	the temperature	Vital signs	through study completion, an average of 2 year.
Primary	blood pressure	Vital signs	through study completion, an average of 2 year.
Primary	complete blood count	laboratory index	through study completion, an average of 2 year.
Primary	adverse event and severe adverse event	adverse event and severe adverse event, according to NCI-CTC V5.0	through study completion, an average of 2 year.
Secondary	Objective Response Rate (ORR)	Objective Response Rate	through study completion, an average of 2 year.
Secondary	disease control rate (DCR)	disease control rate	through study completion, an average of 2 year.